Sitaxsentan

Overview

Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC 50 of 1.4 nM and a K i of 0.43 nM. Sitaxsentan exhibits an IC 50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4 , normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Endothelin Receptor | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-76520
• CAS No.: 184036-34-8
• Molecular Formula: C18H15ClN2O6S2
• Molecular Weight: 454.90
• Purity: 98.96%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution
• Availability: In-stock

Source

Original product source